Sugarbeat latest update
Nemaura Places SugarBEAT® Manufacturer Order for UK Commercial Launch
LOUGHBOROUGH, England–Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing the wireless sugarBEAT® non-invasive glucose monitoring system for adjunctive use by persons with diabetes, today announced it has placed an initial order with its designated UK-based contract manufacturer for 12,500 sugarBEAT® rechargeable transmitters, which will be supplemented with approximately 100,000 skin-patches per month, also manufactured in the UK, in preparation for the anticipated sugarBEAT® product launch in the coming months.
SugarBEAT® consists of a daily-disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five minute intervals, and is expected to launch initially in the United Kingdom, upon CE Mark approval.
Dr Faz Chowdhury, CEO and chair of Nemaura Medical commented ‘We expect this initial order will support the successful launch of sugarBEAT® in the UK later this year, and also develop the capacities needed for subsequent scale up and launch in other countries which accept the CE Mark.’
Nemaura Medical recently completed a sugarBEAT® European three-stage clinical trial program consisting of 75 patients over 525 patient days in total, and have used this data to support their CE Mark application. A predecessor sugarBEAT® device, based on a wired wrist-watch form factor, received CE Mark approval in 2016.
About Nemaura Medical, Inc.
Nemaura Medical Inc. (NASDAQ: NMRD), is a medical technology company developing sugarBEAT® as a non-invasive, affordable and flexible glucose monitoring system for adjunctive use by persons with diabetes.
SugarBEAT® consists of a daily-disposable adhesive skin-patch connected to a rechargeable transmitter, with an app displaying glucose readings at five minute intervals.